Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of ...
Indeed, the pathogen seems like ancient history — but as recent developments indicate, tuberculosis isn’t done with us yet.
Innovative research at Weill Cornell Medicine introduces engineered mycobacteria strains with 'kill switches' for safer TB ...
Rutgers Health experts discuss the infectious disease and the university's role in research and treatment Tuberculosis (TB) ...
Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the ...
Of children aged 5 to 10 years, about 40% had abnormal lung function post-treatment, rising to 65% in older children.
A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...
Tuberculosis (TB) has long been recognized as a disease of poverty, yet most TB research does not measure poverty in a ...
The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...
The tuberculosis outbreak in the Kansas City area is not, in fact, the largest in U.S. history. But it does offer an ...
A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.